Share your videos with the world

Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy

Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy